← Human Trials & Peer-Reviewed Studies
Bone turnover in pregnancy, measured by urinary CTX, is influenced by vitamin D supplementation and is associated with maternal bone health: findings from the Maternal Vitamin D Osteoporosis Study (MAVIDOS) trial.
Plain-language guide to PMID 34297067 (2021): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc, osteoporosis and bone density.
Key Facts
- PMID
- 34297067
- Journal
- The American journal of clinical nutrition
- Year
- 2021
- Study type
- Randomized Controlled Trial
- Authors
- Curtis EM et al. (20 authors)
- DOI
- 10.1093/ajcn/nqab264
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Vitamin D, K2, Magnesium and Zinc in the context of osteoporosis and bone density, published as a randomized controlled trial.
The researchers investigated changes across pregnancy in a marker of maternal bone resorption, urinary C-terminal telopeptide of type I collagen (CTX), the influence of gestational vitamin D supplementation, and associations between CTX and maternal postnatal bone indices.
The Mann-Whitney Rank Sum test, Spearman's rank correlation, and linear regression were used to compare median CTX values within and between groups from early to late pregnancy, and associations with maternal bone outcomes.
Why It Was Studied
The pattern of change in maternal bone turnover throughout pregnancy is poorly characterized.
Who Took Part
The age groups tagged for this paper are adults, women only.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.
A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.
What Was Measured
Topics PubMed links to this paper include Bone Density, Bone Remodeling, Collagen Type I, Dietary Supplements, Peptides and Vitamin D.
Author keywords: CTX, DXA, bone turnover, epidemiology, osteoporosis and pregnancy.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in people with osteoporosis and bone density.
The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2021 (The American journal of clinical nutrition), a journal based in United States.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, Osteoporosis and bone density research.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.